Dr Reddy's Laboratories Total Liabilities 2012-2026 | RDY
Dr Reddy's Laboratories total liabilities from 2012 to 2026. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Dr Reddy's Laboratories total liabilities for the quarter ending June 30, 2026 were $1.991B, a 2.89% increase year-over-year.
- Dr Reddy's Laboratories total liabilities for 2026 were $2.121B, a 16.22% increase from 2025.
- Dr Reddy's Laboratories total liabilities for 2025 were $1.825B, a 42.13% increase from 2024.
- Dr Reddy's Laboratories total liabilities for 2024 were $1.284B, a 16.09% increase from 2023.
|
Dr Reddy's Laboratories Annual Total Liabilities (Millions of US $) |
|
|---|---|
| 2026 | $2,121 |
| 2025 | $1,825 |
| 2024 | $1,284 |
| 2023 | $1,106 |
| 2022 | $1,348 |
| 2021 | $1,264 |
| 2020 | $1,025 |
| 2019 | $1,232 |
| 2018 | $1,523 |
| 2017 | $1,477 |
| 2016 | $1,197 |
| 2015 | $1,339 |
| 2014 | $1,324 |
| 2013 | $1,270 |
| 2012 | $1,219 |
|
Dr Reddy's Laboratories Quarterly Total Liabilities (Millions of US $) |
|
|---|---|
| 2026-06-30 | $1,991 |
| 2026-03-31 | $2,121 |
| 2025-12-31 | $2,083 |
| 2025-09-30 | $2,027 |
| 2025-06-30 | $1,935 |
| 2025-03-31 | $1,825 |
| 2024-12-31 | $1,864 |
| 2024-09-30 | $1,871 |
| 2024-06-30 | $1,448 |
| 2024-03-31 | $1,284 |
| 2023-12-31 | $1,262 |
| 2023-09-30 | $1,131 |
| 2023-06-30 | $1,094 |
| 2023-03-31 | $1,106 |
| 2022-12-31 | $1,076 |
| 2022-09-30 | $1,042 |
| 2022-06-30 | $1,210 |
| 2022-03-31 | $1,348 |
| 2021-12-31 | $1,243 |
| 2021-09-30 | $1,277 |
| 2021-06-30 | $1,347 |
| 2021-03-31 | $1,264 |
| 2020-12-31 | $1,136 |
| 2020-09-30 | $1,197 |
| 2020-06-30 | $1,185 |
| 2020-03-31 | $1,025 |
| 2019-12-31 | $970 |
| 2019-09-30 | $1,133 |
| 2019-06-30 | $1,174 |
| 2019-03-31 | $1,232 |
| 2018-12-31 | $1,307 |
| 2018-09-30 | $1,417 |
| 2018-06-30 | $1,467 |
| 2018-03-31 | $1,523 |
| 2017-12-31 | $1,602 |
| 2017-09-30 | $1,534 |
| 2017-06-30 | $1,470 |
| 2017-03-31 | $1,477 |
| 2016-12-31 | $1,563 |
| 2016-09-30 | $1,579 |
| 2016-06-30 | $1,206 |
| 2016-03-31 | $1,197 |
| 2015-12-31 | $1,197 |
| 2015-09-30 | $1,236 |
| 2015-06-30 | $1,294 |
| 2015-03-31 | $1,339 |
| 2014-12-31 | $1,258 |
| 2014-09-30 | $1,249 |
| 2014-06-30 | $1,279 |
| 2014-03-31 | $1,324 |
| 2013-12-31 | $1,340 |
| 2013-09-30 | $1,327 |
| 2013-06-30 | $1,275 |
| 2013-03-31 | $1,270 |
| 2012-12-31 | $1,295 |
| 2012-09-30 | $1,273 |
| 2012-06-30 | $1,205 |
| 2012-03-31 | $1,219 |
| 2011-12-31 | $1,330 |
| 2011-09-30 | $1,218 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $9.749B | $3.580B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |